Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)

Onco360, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy (sunvozertinib), a kinase inhibitor indicated for treating adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The partnership expands Onco360's existing relationship with AstraZeneca and leverages its oncology platform to support patient access and care.